<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0161106</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-15956</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Clinical genetics</subject><subj-group><subject>Genetic diseases</subject><subj-group><subject>Autosomal dominant diseases</subject><subj-group><subject>Huntington disease</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodegenerative diseases</subject><subj-group><subject>Huntington disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive science</subject><subj-group><subject>Cognitive neuroscience</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive neuroscience</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cognitive neurology</subject><subj-group><subject>Cognitive impairment</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Behavior</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Heredity</subject><subj-group><subject>Genetic mapping</subject><subj-group><subject>Variant genotypes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Prefrontal cortex</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Prefrontal cortex</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive science</subject><subj-group><subject>Cognition</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social sciences</subject><subj-group><subject>Sociology</subject><subj-group><subject>Education</subject><subj-group><subject>Educational attainment</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Neostriatum</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Brain</subject><subj-group><subject>Neostriatum</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title><italic>COMT</italic> Val<sup>158</sup>Met Polymorphism Modulates Huntington's Disease Progression</article-title>
<alt-title alt-title-type="running-head"><italic>COMT</italic> Polymorphism in Huntington's Disease</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>de Diego-Balaguer</surname>
<given-names>Ruth</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Schramm</surname>
<given-names>Catherine</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Rebeix</surname>
<given-names>Isabelle</given-names>
</name>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Dupoux</surname>
<given-names>Emmanuel</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff010"><sup>10</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Durr</surname>
<given-names>Alexandra</given-names>
</name>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff011"><sup>11</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Brice</surname>
<given-names>Alexis</given-names>
</name>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff011"><sup>11</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Charles</surname>
<given-names>Perrine</given-names>
</name>
<xref ref-type="aff" rid="aff011"><sup>11</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Cleret de Langavant</surname>
<given-names>Laurent</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff012"><sup>12</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Youssov</surname>
<given-names>Katia</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff012"><sup>12</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Verny</surname>
<given-names>Christophe</given-names>
</name>
<xref ref-type="aff" rid="aff013"><sup>13</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Damotte</surname>
<given-names>Vincent</given-names>
</name>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Azulay</surname>
<given-names>Jean-Philippe</given-names>
</name>
<xref ref-type="aff" rid="aff014"><sup>14</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Goizet</surname>
<given-names>Cyril</given-names>
</name>
<xref ref-type="aff" rid="aff015"><sup>15</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Simonin</surname>
<given-names>Cl√©mence</given-names>
</name>
<xref ref-type="aff" rid="aff016"><sup>16</sup></xref>
<xref ref-type="aff" rid="aff017"><sup>17</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tranchant</surname>
<given-names>Christine</given-names>
</name>
<xref ref-type="aff" rid="aff018"><sup>18</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Maison</surname>
<given-names>Patrick</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff019"><sup>19</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Rialland</surname>
<given-names>Amandine</given-names>
</name>
<xref ref-type="aff" rid="aff019"><sup>19</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Schmitz</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff019"><sup>19</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Jacquemot</surname>
<given-names>Charlotte</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Fontaine</surname>
<given-names>Bertrand</given-names>
</name>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
<xref ref-type="aff" rid="aff011"><sup>11</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Bachoud-L√©vi</surname>
<given-names>Anne-Catherine</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff012"><sup>12</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<collab>the French Speaking Huntington Group</collab>
<xref ref-type="fn" rid="fn001"><sup>¬∂</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>INSERM U955, Equipe 01 Neuropsychologie Interventionnelle, 94000, Cr√©teil, France</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>D√©partement d‚ÄôEtudes Cognitives, Ecole Normale Sup√©rieure, PSL Research University, 75005, Paris, France</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Universit√© Paris Est, Facult√© de M√©decine, 94000, Cr√©teil, France</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>ICREA, 08010, Barcelona, Spain</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Universitat de Barcelona, Departament de Cognici√≥, Desenvolupament i Psicologia de L‚ÄôEducaci√≥, 08035, Barcelona, Spain</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>IDIBELL, Unitat de Cognici√≥ i Plasticitat Cerebral, 08907, L‚ÄôHospitalet de Llobregat, Spain</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Institut de Neuroci√®ncia, Universitat de Barcelona, Barcelona, Spain</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>INSERM-UPMC-CNRS, UMR 7225‚Äì1127, Institut Cerveau Moelle-ICM, H√¥pital Piti√©-Salp√™tri√®re, 74013, Paris, France</addr-line></aff>
<aff id="aff009"><label>9</label> <addr-line>Assistance Publique-H√¥pitaux de Paris, D√©partement des Maladies du Syst√®me Nerveux, H√¥pital Piti√©-Salp√™tri√®re, 74013, Paris, France</addr-line></aff>
<aff id="aff010"><label>10</label> <addr-line>Laboratoire de Sciences Cognitives et Psycholinguistique, ENS-EHESS-CNRS, Paris, 75005, France</addr-line></aff>
<aff id="aff011"><label>11</label> <addr-line>Assistance Publique-H√¥pitaux de Paris, D√©partement de G√©n√©tique, H√¥pital Piti√©-Salp√™tri√®re, 74013, Paris, France</addr-line></aff>
<aff id="aff012"><label>12</label> <addr-line>Assistance Publique-H√¥pitaux de Paris, Centre de R√©f√©rence Maladie de Huntington, Service de Neurologie, H√¥pital Henri Mondor-Albert Chenevier, 94000, Cr√©teil, France</addr-line></aff>
<aff id="aff013"><label>13</label> <addr-line>CHU d'Angers, Centre de R√©f√©rence des Maladies Neurog√©n√©tiques, Service de Neurologie, 49933, Angers, France</addr-line></aff>
<aff id="aff014"><label>14</label> <addr-line>CHU de Marseille‚ÄîH√¥pital de la Timone, Service de Neurologie et Pathologie du Mouvement, 13385, Marseille, France</addr-line></aff>
<aff id="aff015"><label>15</label> <addr-line>CHU de Bordeaux-GH Sud‚ÄîH√¥pital Haut-L√©v√™que, Service de Neurologie, 33604, Pessac, France</addr-line></aff>
<aff id="aff016"><label>16</label> <addr-line>CHRU de Lille, Service de Neurologie et Pathologie du Mouvement, 59000, Lille, France</addr-line></aff>
<aff id="aff017"><label>17</label> <addr-line>INSERM UMR-S 1172, JPArc, centre de recherche Jean-Pierre-Aubert neurosciences et cancer, Universit√© de Lille, 59000, Lille, France</addr-line></aff>
<aff id="aff018"><label>18</label> <addr-line>CHU de Strasbourg‚ÄîH√¥pital de Hautepierre, Service de Neurologie, 67098, Strasbourg, France</addr-line></aff>
<aff id="aff019"><label>19</label> <addr-line>Assistance Publique-H√¥pitaux de Paris, H√¥pital Henri Mondor, Unit√© de Recherche Clinique, 94000, Cr√©teil, France</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Blum</surname>
<given-names>David</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Centre de Recherche Jean-Pierre Aubert, FRANCE</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>R. de Diego-Balaguer, C. Schramm, I. Rebeix, E. Dupoux, A. Durr, A. Brice, P. Charles, L. Cleret de Langavant, K. Youssov, G. F√©nelon, C. Verny, V. Damotte, JP Azulay, C. Simonin, C. Tranchant, P. Maison, A. Rialland, D. Schmitz, C. Jacquemot, B. Fontaine have nothing to disclose. A.C. Bachoud-L√©vi acted as a consultant once for Teva in 2014 and reports grants from the National Reference Center for Huntington‚Äôs Disease from the Ministry of Health and from the clinical research directorate (AP-HP). C. Goizet reports grants from the European Huntington Disease Network and the Programme Hospitalier de Recherche Clinique (PHRC) during the duration of the study; personal fees came from Raptor Pharmaceutical France, Genzyme, and Actelion; grants from Genzyme, Association Fran√ßaise contre les myopathies (AFM), Association Strumpell-Lorrain (ASL), Conna√Ætre les Syndromes C√©r√©belleux (CSC), Union Nationale des Aveugles et D√©ficients Visuels (UNADEV), Conseil R√©gional d‚ÄôAquitaine (CRA), Agence Nationale pour la Recherche (ANR), Programme Hospitalier de Recherche Clinique (PHRC), Genzyme, Actelion, and Biomarin, not covering the work submitted here. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple">
<list-item><p><bold>Conceptualization:</bold> ACBL RDB BF CJ ED.</p></list-item>
<list-item><p><bold>Data curation:</bold> C. Schramm AR DS.</p></list-item>
<list-item><p><bold>Formal analysis:</bold> C. Schramm ED.</p></list-item>
<list-item><p><bold>Funding acquisition:</bold> ACBL BF.</p></list-item>
<list-item><p><bold>Investigation:</bold> ACBL AD IR PC KY CV VD JPA CG C. Simonin CT.</p></list-item>
<list-item><p><bold>Methodology:</bold> ACBL C. Schramm PM BF.</p></list-item>
<list-item><p><bold>Project administration:</bold> ACBL.</p></list-item>
<list-item><p><bold>Resources:</bold> ACBL BF AB.</p></list-item>
<list-item><p><bold>Software:</bold> C. Schramm.</p></list-item>
<list-item><p><bold>Supervision:</bold> ACBL.</p></list-item>
<list-item><p><bold>Validation:</bold> C. Schramm.</p></list-item>
<list-item><p><bold>Writing ‚Äì original draft:</bold> ACBL BF RDB C. Schramm CJ LCL.</p></list-item>
<list-item><p><bold>Writing ‚Äì review &amp; editing:</bold> ACBL BF RDB C. Schramm CJ LCL IR ED AD AB PC KY CV VD JPA CG C. Simonin CT PM AR DS.</p></list-item></list></p>
</fn>
<fn fn-type="other" id="fn001">
<p>¬∂ Membership of the French Speaking Huntington Group is listed in the Acknowledgments.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">bachoud@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>9</issue>
<elocation-id>e0161106</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>de Diego-Balaguer et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0161106"/>
<abstract>
<p>Little is known about the genetic factors modulating the progression of Huntington‚Äôs disease (HD). Dopamine levels are affected in HD and modulate executive functions, the main cognitive disorder of HD. We investigated whether the Val<sup>158</sup>Met polymorphism of the <italic>catechol-O-methyltransferase</italic> (<italic>COMT</italic>) gene, which influences dopamine (DA) degradation, affects clinical progression in HD. We carried out a prospective longitudinal multicenter study from 1994 to 2011, on 438 HD gene carriers at different stages of the disease (34 pre-manifest; 172 stage 1; 130 stage 2; 80 stage 3; 17 stage 4; and 5 stage 5), according to Total Functional Capacity (TFC) score. We used the Unified Huntington‚Äôs Disease Rating Scale to evaluate motor, cognitive, behavioral and functional decline. We genotyped participants for <italic>COMT</italic> polymorphism (107 Met-homozygous, 114 Val-homozygous and 217 heterozygous). 367 controls of similar ancestry were also genotyped. We compared clinical progression, on each domain, between groups of <italic>COMT</italic> polymorphisms, using latent-class mixed models accounting for disease duration and number of CAG (cytosine adenine guanine) repeats. We show that HD gene carriers with fewer CAG repeats and with the Val allele in <italic>COMT</italic> polymorphism displayed slower cognitive decline. The rate of cognitive decline was greater for Met/Met homozygotes, which displayed a better maintenance of cognitive capacity in earlier stages of the disease, but had a worse performance than Val allele carriers later on. <italic>COMT</italic> polymorphism did not significantly impact functional and behavioral performance. Since <italic>COMT</italic> polymorphism influences progression in HD, it could be used for stratification in future clinical trials. Moreover, DA treatments based on the specific <italic>COMT</italic> polymorphism and adapted according to disease duration could potentially slow HD progression.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100006587</institution-id>
<institution>GIS-Institut des Maladies Rares</institution>
</institution-wrap>
</funding-source>
<award-id>A02216JS /A04159JS</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Bachoud-L√©vi</surname>
<given-names>Anne-Catherine</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004571</institution-id>
<institution>Minist√®re des Affaires Sociales et de la Sant√©</institution>
</institution-wrap>
</funding-source>
<award-id>Interface</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Bachoud-L√©vi</surname>
<given-names>Anne-Catherine</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003329</institution-id>
<institution>Ministerio de Econom√≠a y Competitividad</institution>
</institution-wrap>
</funding-source>
<award-id>PSI2011-23624</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>de Diego-Balaguer</surname>
<given-names>Ruth</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution>Seventh Framework Programme (BE)</institution>
</funding-source>
<award-id>222943</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Schramm</surname>
<given-names>Catherine</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-11-INBS-0011 ‚Äì NeurATRIS n¬∞23624</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Schramm</surname>
<given-names>Catherine</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-10-LBX-0087 IEC</award-id>
</award-group>
<award-group id="award007">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-10-IDEX-0001-02 PSL*</award-id>
</award-group>
<award-group id="award008">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-11-INBS-0011 ‚Äì NeurATRIS n¬∞23624</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Cleret de Langavant</surname>
<given-names>Laurent</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award009">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-10-IAIHU-06</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Durr</surname>
<given-names>Alexandra</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award010">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-10-IAIHU-06</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Rebeix</surname>
<given-names>Isabelle</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award011">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-10-IAIHU-06</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Brice</surname>
<given-names>Alexis</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award012">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-10-IAIHU-06</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Damotte</surname>
<given-names>Vincent</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award013">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001665</institution-id>
<institution>Agence Nationale de la Recherche</institution>
</institution-wrap>
</funding-source>
<award-id>ANR-10-IAIHU-06</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Fontaine</surname>
<given-names>Bertrand</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>A-C Bachoud-L√©vi is the PI of the biomarker program initially funded by Gis A02216JS/A04159JS and then by Assistance Publique‚ÄîH√¥pitaux de Paris (D√©partement de la Recherche Clinique et du D√©veloppement); she had full access to all of the data for this study and takes responsibility for the integrity of the data and the accuracy of data analysis. She is supported by an interface contract from INSERM and is the Head of the French National Center for Huntington‚Äôs Disease (funded by the French Ministry of Health). R de Diego-Balaguer was supported by grant PSI2011-23624 from the Ministerio de Econom√≠a y Competitividad (MINECO). C Schramm was supported by the NeuroStemcell Consortium (European Community Seventh Framework Program grant agreement no. 222943) and by investment for the future NeurATRIS: Infrastructure de recherche translationnelle pour les bioth√©rapies en Neurosciences (ANR-11-INBS-0011). Additional support was provided by ANR-10-LBX-0087 IEC and ANR-10-IDEX-0001-02 PSL* grants. A D√ºrr, A Brice, V Damotte, I Rebeix and B Fontaine were supported by IHU grant ANR-10-IAIHU-06. L Cleret de Langavant was supported by an AP-HP/CEA interface contract. The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="3"/>
<page-count count="18"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>Any person requesting the data should ask Professor AC Bachoud-L√©vi (<email xlink:type="simple">anne-catherine.bachoud-levi@aphp.fr</email>) for the data and meet the criteria for access to confidential data. Indeed, patients had signed an inform consent form ensuring the data confidentiality. This consent stipulates that the authors must guarantee the confidentiality of the data and does not allow them to share the data in a open access repository. However, they will provide data upon request, following two constraints: 1) The requestor should sign a confidentiality agreement that the authors' institution will provide. He/she must provide a description of the purpose of the study using the data. The contract will specify that the data will be used only for research publications and not for any other purposes, and that the researcher will not try in any way to identify the patient. 2) Because the data are issued from small cohorts, identification of the patients is feasible using center names and/or dates of assessments. Thus, in addition, this information will be cancelled to prevent the patients' identification. The authors will provide the data with the inter-visits delay to allow for proper statistics.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Huntington‚Äôs disease (HD) is an autosomal dominant inherited neurodegenerative disease caused by increased number of CAG (cytosine adenine guanine) repeats in the Huntingtin (<italic>Htt</italic>) gene on chromosome 4 [<xref ref-type="bibr" rid="pone.0161106.ref001">1</xref>]. It primarily affects the striatum and manifests as progressive motor, behavioral and cognitive disturbances, leading to death about 15 to 20 years after onset. There is currently no effective course-modifying treatment.</p>
<p>Phenotypic expression differs considerably between patients. Age at onset varies and few of the underlying genetic factors for this variability have been identified [<xref ref-type="bibr" rid="pone.0161106.ref002">2</xref>]. The size of the number of CAG repeats in the mutated <italic>Htt</italic> (<italic>mHtt</italic>) gene is inversely related to age at onset of HD patients, but accounts for only 40 to 70% of its variance [<xref ref-type="bibr" rid="pone.0161106.ref003">3</xref>]. The implication of other genes in HD such as the <italic>PPARGC1A</italic>, <italic>GRIK2</italic>, <italic>APOE</italic> and <italic>BDNF</italic> genes, has been shown, but their impact was not replicated in subsequent studies [<xref ref-type="bibr" rid="pone.0161106.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0161106.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0161106.ref006">6</xref>]. The factors influencing disease progression remain to be identified [<xref ref-type="bibr" rid="pone.0161106.ref007">7</xref>]. Higher number of CAG repeats in the <italic>mHtt</italic> gene is associated with faster motor, cognitive, and functional decline [<xref ref-type="bibr" rid="pone.0161106.ref008">8</xref>]. The influence of the number of CAG repeats in the normal <italic>Htt</italic> allele remains uncertain, either on age at onset or disease progression [<xref ref-type="bibr" rid="pone.0161106.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0161106.ref009">9</xref>].</p>
<p>Here, in addition to results provided by genome wide association mapping conducted on the motor onset [<xref ref-type="bibr" rid="pone.0161106.ref010">10</xref>], we conduct an <italic>a priori</italic> study on the <italic>catechol-O-methyltransferase</italic> (<italic>COMT</italic>) to assess its impact on HD evolution [<xref ref-type="bibr" rid="pone.0161106.ref011">11</xref>]. COMT may play a role in HD because it degrades catecholamines, such as dopamine (DA). Medium-sized striatal spiny GABAergic neurons bearing dopaminergic receptors (D1 and D2) are preferentially affected in HD [<xref ref-type="bibr" rid="pone.0161106.ref012">12</xref>]. The density of these receptors in the striatum decreases [<xref ref-type="bibr" rid="pone.0161106.ref013">13</xref>] along with DA and GABA concentrations in HD patients. DA receptors loss correlates with disease progression in mouse HD models [<xref ref-type="bibr" rid="pone.0161106.ref014">14</xref>]. Furthermore, DA receptors dysfunction is correlated with cognitive impairment in HD gene carriers [<xref ref-type="bibr" rid="pone.0161106.ref015">15</xref>]. In the normal population, the presence of a Valine instead of a Methionine in position 158 (Val<sup>158</sup>Met) on the <italic>COMT</italic> gene on chromosome 22 increases <italic>COMT</italic> activity to levels 38% higher for the Val/Val genotype than for the Met/Met genotype [<xref ref-type="bibr" rid="pone.0161106.ref016">16</xref>], resulting in lower DA levels in Val/Val homozygotes. <italic>COMT</italic> polymorphism essentially affects DA levels in the prefrontal cortex (PFC), whereas striatal DA level is regulated principally by the DA transporter (DAT). However, there is an interaction between <italic>DAT</italic> and <italic>COMT</italic> genes in the regulation of DA level in the fronto-striatal system [<xref ref-type="bibr" rid="pone.0161106.ref017">17</xref>]. Indeed, <italic>COMT</italic> polymorphism influences the severity of cognitive and behavioral symptoms in other diseases affecting subcortical DA regulation, such as Parkinson‚Äôs disease [<xref ref-type="bibr" rid="pone.0161106.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0161106.ref019">19</xref>] and schizophrenia [<xref ref-type="bibr" rid="pone.0161106.ref020">20</xref>], and is predictive of disease progression and psychosis in 22q11.2 deletion syndrome [<xref ref-type="bibr" rid="pone.0161106.ref021">21</xref>], another disease related to striatal dysfunction. Additionally, in early stages of Huntington‚Äôs disease the PFC function appears to have an important role in compensation of cognitive impairment [<xref ref-type="bibr" rid="pone.0161106.ref022">22</xref>].</p>
<p>In HD, <italic>COMT</italic> polymorphism has no influence on motor onset [<xref ref-type="bibr" rid="pone.0161106.ref004">4</xref>], but its effect in behavioral, cognitive and functional domains has not been investigated except in a very recent study. In a cross-sectional study of 121 HD patients, Vinther-Jensen et al [<xref ref-type="bibr" rid="pone.0161106.ref023">23</xref>] found that <italic>COMT</italic> and <italic>MAOA</italic> polymorphism were associated with behavioral symptoms or cognitive impairment, respectively. The link between polymorphisms in genes involved in the dopaminergic pathway and the behavioral and cognitive symptoms highlights the role of dopamine regulation in HD symptomatology. However, patients were not assessed longitudinally, and the impact of <italic>COMT</italic> polymorphism in disease progression remains unexplored.</p>
<p>The cognitive effects of <italic>COMT</italic> polymorphism in various diseases and in healthy populations have repeatedly been reported to be specific to executive functions (see [<xref ref-type="bibr" rid="pone.0161106.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0161106.ref025">25</xref>] for reviews), and executive function defects are the hallmark of cognitive dysfunction in HD. Furthermore, even at low doses, DA aggravates <italic>mHtt</italic> toxicity in striatal neuron cultures [<xref ref-type="bibr" rid="pone.0161106.ref026">26</xref>] and increases behavioral and motor deficits in YAC128 mice [<xref ref-type="bibr" rid="pone.0161106.ref027">27</xref>], a transgenic model of HD. Thus, <italic>COMT</italic> polymorphism may affect the progression of HD.</p>
<p>In this study, we investigated the impact of <italic>COMT</italic> polymorphism on HD progression on cognitive, motor, behavioral and functional decline, in a longitudinal long-term prospective study.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Material and Methods</title>
<sec id="sec003">
<title>Participants</title>
<p>We report a longitudinal prospective long-term study of 438 HD gene carriers from the Predictive Biomarkers for Huntington‚Äôs disease protocol (NCT01412125), which was approved by the ethics committee of Henri Mondor Hospital (Cr√©teil, France) in accordance with EU and French bioethics laws. All HD gene carriers gave written informed consent. They were heterozygous for the <italic>Htt</italic> gene (&gt; 36 CAG repeats in <italic>mHtt</italic>) and aware of their genetic status. They had no other neurological conditions or long-term experimental treatment (e.g. cell transplantation).</p>
<p>Data were collected from 1994 to 2011, at eight centers from the French Speaking Huntington‚Äôs Disease Group (Angers: 24%, Bordeaux: 7%, Cr√©teil: 34%, Lille: 4%, Lyon: 1%, Marseille: 12%, Paris: 11%, Strasbourg: 7%), and centralized at the National Reference Centre for Huntington‚Äôs disease in Cr√©teil.</p>
<p>Blood samples were centralized at the DNA bank of Piti√©-Salp√™tri√®re Hospital. The number of CAG repeats was routinely determined [<xref ref-type="bibr" rid="pone.0161106.ref028">28</xref>]. The rs4680 (<italic>COMT</italic> Val<sup>158</sup>Met) polymorphism was genotyped by PCR with appropriate primers [<xref ref-type="bibr" rid="pone.0161106.ref029">29</xref>]. We investigated the distribution of <italic>COMT</italic> genotypes in the general population, by genotyping 367 independent controls with similar ancestry with the same technique.</p>
</sec>
<sec id="sec004">
<title>Clinical assessment</title>
<p>HD gene carriers were followed up with the Unified Huntington‚Äôs Disease Rating Scale (UHDRS) [<xref ref-type="bibr" rid="pone.0161106.ref030">30</xref>], which combines motor, functional, behavioral and cognitive assessments. Motor domain was assessed using the Total Motor Score (TMS, range: 0 to 124). Functional domain was assessed using the Total Functional Capacity scale (TFC, range: 13 to 0), Functional Assessment Scale (FAS, range: 25 to 50) and Independence Scale (IS, range: 100 to 0). Behavioral domain was assessed using the psychiatric part of the UHDRS (range: 0 to 88). Cognitive domain was assessed using the Stroop Test (color naming: Stroop C, word reading: Stroop W, and color-word interference: Stroop C/W), Symbol Digit Modality Test (SDMT), and letter fluency (for P, R and V in French). For letter fluency, testing at two minutes appears to be more sensitive than testing at one minute [<xref ref-type="bibr" rid="pone.0161106.ref031">31</xref>]. The French version used in this study includes both measurements. Higher scores in IS, FAS and TMS indicate greater impairment. For all other tasks, higher scores indicate lower impairment.</p>
<p>The first evaluation corresponding to the entrance in the study (first visit) occurred before onset (pre-manifest) in some individuals and at various times after onset in others, such that the sample encompassed the entire spectrum of HD progression (first visit: 8% pre-manifest gene carriers; 39% patients at Stage 1; 30% Stage 2; 18% Stage 3; 4% stage 4; and 1% Stage 5). Pre-manifest gene carriers were defined as having a TMS below or equal to 5 [<xref ref-type="bibr" rid="pone.0161106.ref032">32</xref>], and a TFC score of 13. The visits were performed annually, with few exceptions, with a mean inter-visit delay of 1.2 years (SD = 0.4). The mean number of visits per HD gene carriers was 5.0 (SD = 3.2; range: 1 to 19 visits). Thirty-two HD gene carriers were seen only once. Data were recorded for 2185 visits. The mean duration of follow-up was 4.3 years for the whole cohort (SD = 3.0; range: 0 to 15.5 years), and 4.8 years (SD = 2.9) years when excluding patients assessed once.</p>
<p>The date at onset was available for 86.53% of the HD gene carriers. It corresponds to the appearance of the first symptoms, and it was determined (observed) by the clinician (93.14%), or, if missing, by the family (5.28%), or, if missing that as well, by the participant (1.58%).</p>
</sec>
<sec id="sec005">
<title>Statistical analyses</title>
<sec id="sec006">
<title>Demographics and characteristics of COMT polymorphism groups at the first visit</title>
<p>The œá<sup>2</sup> goodness-of-fit test was computed to compare the distribution of <italic>COMT</italic> genotypes in the 438 HD gene carriers and in the control group. Stability of the genotype frequency was assessed through the Hardy-Weinberg test in controls.</p>
<p>We assessed whether baseline characteristics of HD gene carriers were similar in the different <italic>COMT</italic> polymorphism samples (Met/Met, Val/Val and Met/Val), by first assessing the differences between groups for each score of the UHDRS at the first visit. Demographic data and clinical characteristics of the sample (N = 438) at the first visit were compared between groups, with a Pearson‚Äôs œá<sup>2</sup> tests for qualitative variables and a one-way ANOVA for quantitative variables. For variables with significant difference between groups, student‚Äôs <italic>t</italic>-tests (or Welch‚Äôs tests in cases of unequal variances) were performed with Bonferroni correction for multiple pairwise comparisons (see <xref ref-type="supplementary-material" rid="pone.0161106.s004">S1 Table</xref> for the same comparisons in the subgroup included in the longitudinal analysis).</p>
</sec>
<sec id="sec007">
<title>Number of CAG repeats and age at onset</title>
<p>We first assessed the impact of the number of CAG repeats on age at onset in the 379 HD gene carriers with these available data. We used a linear regression model, with age at onset as the dependent variable and the number of CAG repeats as an independent variable. The R<sup>2</sup> value provided by the model is an estimate of the proportion of the variability of the age at onset explained by the number CAG repeats.</p>
<p>We also calculated an expected age at onset according to the Langbehn et al. model [<xref ref-type="bibr" rid="pone.0161106.ref033">33</xref>], derived from the number of CAG repeats using the formula: <italic>expected age = (21</italic>.<italic>54 + exp (9</italic>.<italic>556‚Äì0</italic>.<italic>146*CAG))</italic>. We evaluated the agreement between this expected age at onset and the age at onset provided in our database by calculating the intraclass correlation coefficient (ICC), a measure for concordance. The ICC was obtained by a two-way mixed effect model [<xref ref-type="bibr" rid="pone.0161106.ref034">34</xref>].</p>
</sec>
<sec id="sec008">
<title>Longitudinal analysis of disease progression</title>
<p>The longitudinal analysis was conducted on 1912 visits of the 350 HD gene carriers with at least two visits and for which the date of onset was known.</p>
<p>We compared progression over time between groups, by calculating the overall change in motor, functional, behavioral and cognitive domains per year since the date of onset. Domains are not observable <italic>per se</italic> but are modeled by a latent variable reflected by observed performances at each task. We performed four latent-class mixed models [<xref ref-type="bibr" rid="pone.0161106.ref035">35</xref>], one per domain, where each model combines: (i) a linear mixed model to explain latent domain according to covariates, and (ii) beta transformations which link observed performances at each task to latent domain (<xref ref-type="fig" rid="pone.0161106.g001">Fig 1</xref>). Similarly to classical linear mixed models, the latent-class mixed model allows integrating data from HD gene carriers with unequal duration of follow-up and introducing a subject-specific intercept by random effects to account for within-unit correlation for outcome and between-subject variability [<xref ref-type="bibr" rid="pone.0161106.ref036">36</xref>]. These models take into account all observations for each patient, without listwise deletion. Moreover, the use of beta transformations allows taking into account the ceiling and floor effects of UHDRS tasks.</p>
<fig id="pone.0161106.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Structure of the latent class mixed models.</title>
<p>Red dashed line includes variables used for the linear mixed model part. Blue dashed line includes variables used for the beta transformation. Latent domain represents the non-observable motor, behavioral, functional or cognitive domains. Observed task performances are those measured using the UHDRS. The latent motor process was modeled using the TMS; the latent behavioral process was modeled using the UHDRS behavioral score; the latent functional process was modeled using the FAS and IS scores; The latent cognitive process was modeled using letter fluency at 1 minute, letter fluency at 2 minutes, SDMT, Stroop Color, Stroop Word and Stroop Word/Color interference.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.g001" xlink:type="simple"/>
</fig>
<p>Parameters of linear mixed model and beta transformations are estimated simultaneously using maximum likelihood method and Monte-Carlo integration. The disease duration (time since onset), <italic>COMT</italic> polymorphism, number of CAG repeats in <italic>mHtt</italic>, interaction between disease duration and the number of CAG repeats, interaction between disease duration and <italic>COMT</italic> polymorphism, gender [<xref ref-type="bibr" rid="pone.0161106.ref037">37</xref>] and education level were retained as covariates. For <italic>COMT</italic> polymorphism, included in the model as a categorical covariate, Met/Met was the reference group, allowing the comparison between Met/Met and Val/Val genotypes and between Met/Met and Met/Val genotypes. We compared Met/Val and Val/Val genotypes by recomputing the models with Met/Val genotype as the reference group. All <italic>P</italic>-values were adjusted with Bonferroni correction in two steps: one within the <italic>COMT</italic> polymorphism groups comparison and one for multiple comparisons across domains. Based on Akaike‚Äôs information criterion and Bayesian information criterion [<xref ref-type="bibr" rid="pone.0161106.ref038">38</xref>], number of CAG repeats in the normal <italic>Htt</italic> allele and CAG-<italic>COMT</italic> interaction did not improve model fit, thus they were removed from the final model. Similarly, accounting for the age at onset rather than for the number of CAG repeats did not improve model fit.</p>
<p>To assess the robustness of the results, a sensitivity analysis was performed excluding outliers, on the basis of the number of CAG repeats and of the distribution of dates of visits in our cohort (see <xref ref-type="supplementary-material" rid="pone.0161106.s001">S1 Fig</xref> and <xref ref-type="supplementary-material" rid="pone.0161106.s002">S2 Fig</xref>). The sensitivity analysis included HD gene carriers with a number of CAG repeats between 39 and 49 that were followed in the 20 years after disease onset.</p>
<p>Analyses were conducted with R 2.3 software (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/" xlink:type="simple">http://www.r-project.org/</ext-link>). The R package lcmm was used to perform the longitudinal analysis. All tests were two-tailed. Values of <italic>P</italic> &lt; 0.05 were considered significant.</p>
</sec>
</sec>
</sec>
<sec id="sec009" sec-type="results">
<title>Results</title>
<sec id="sec010">
<title>Demographics and characteristics of COMT polymorphism groups at the first visit</title>
<p>The œá<sup>2</sup> goodness-of-fit test confirms that the distribution of <italic>COMT</italic> genotypes is similar in HD gene carriers and the control group (<italic>P</italic> = 0.15) (see <xref ref-type="table" rid="pone.0161106.t001">Table 1</xref>). The genotype frequencies remain constant from generation to generation (Hardy-Weinberg <italic>P</italic> = 0.13).</p>
<table-wrap id="pone.0161106.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.t001</object-id>
<label>Table 1</label> <caption><title>Distribution of the <italic>COMT</italic> genotypes in HD gene carriers and control groups.</title></caption>
<alternatives>
<graphic id="pone.0161106.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center">Met/Met</th>
<th align="center">Met/Val</th>
<th align="center">Val/Val</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Controls <italic>N</italic> (%)</td>
<td align="center">70 (19.1)</td>
<td align="center">202 (55.0)</td>
<td align="center">95 (25.9)</td>
</tr>
<tr>
<td align="left">HD gene carriers <italic>N</italic> (%)</td>
<td align="center">107 (24.4)</td>
<td align="center">217 (49.6)</td>
<td align="center">114 (26.0)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>HD: Huntington‚Äôs disease; Met: Methionine; Val: Valine</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Demographic and clinical data of HD gene carriers for the first visit are displayed in <xref ref-type="table" rid="pone.0161106.t002">Table 2</xref>. Baseline demographic and clinical characteristics are similar for all <italic>COMT</italic> polymorphisms (one-way ANOVA, <italic>P</italic> &gt; 0.05) except that HD gene carriers with the Met/Val genotype have a lower educational level than those with the Val/Val (pairwise comparison, corrected <italic>P</italic> = 0.01) or Met/Met (pairwise comparison, corrected <italic>P</italic> = 0.01) genotypes. Descriptive analysis of HD gene carriers included in the longitudinal analysis is provided on <xref ref-type="supplementary-material" rid="pone.0161106.s004">S1 Table</xref>. <italic>COMT</italic> polymorphism does not impact age at onset.</p>
<table-wrap id="pone.0161106.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.t002</object-id>
<label>Table 2</label> <caption><title>Demographic characteristics and performance of HD gene carriers.</title></caption>
<alternatives>
<graphic id="pone.0161106.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center">N</th>
<th align="center">Met/Met</th>
<th align="center">Met/Val</th>
<th align="center">Val/Val</th>
<th align="center"><italic>P<xref ref-type="table-fn" rid="t002fn002">*</xref></italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Age (yrs)</td>
<td align="center">438</td>
<td align="center">46.1 (12.8)</td>
<td align="center">49.5 (12.1)</td>
<td align="center">47.9 (11.2)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Sex (% men)</td>
<td align="center">438</td>
<td align="center">55.1</td>
<td align="center">47.0</td>
<td align="center">52.6</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Age at onset (yrs)</td>
<td align="center">379</td>
<td align="center">41.9 (11.6)</td>
<td align="center">45.3 (11.5)</td>
<td align="center">43.6 (9.7)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Educational level (yrs in education)</td>
<td align="center">435</td>
<td align="center">12.3 (3.4)</td>
<td align="center">11.2 (2.9)</td>
<td align="center">12.2 (3.3)</td>
<td align="center">0.0012</td>
</tr>
<tr>
<td align="left">BMI</td>
<td align="center">382</td>
<td align="center">22.6 (3.7)</td>
<td align="center">22.7 (3.6)</td>
<td align="center">22.1 (3.5)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">CAG repeats <italic>mHtt</italic></td>
<td align="center">438</td>
<td align="center">45.3 (4.5)</td>
<td align="center">44.5 (3.6)</td>
<td align="center">44.6 (3.1)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">CAG repeats <italic>Htt</italic></td>
<td align="center">438</td>
<td align="center">18.3 (2.8)</td>
<td align="center">18.9 (4.1)</td>
<td align="center">18.9 (3.9)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Antipsychotic use (%)</td>
<td align="center">438</td>
<td align="center">75.7</td>
<td align="center">73.3</td>
<td align="center">72.8</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Antidepressant use (%)</td>
<td align="center">438</td>
<td align="center">28.0</td>
<td align="center">27.6</td>
<td align="center">28.1</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Benzodiazepine use (%)</td>
<td align="center">438</td>
<td align="center">24.3</td>
<td align="center">23.0</td>
<td align="center">14.0</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left"><bold>UHDRS</bold></td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left">TMS</td>
<td align="center">421</td>
<td align="center">30.6 (19.7)</td>
<td align="center">32.3 (22.0)</td>
<td align="center">35.9 (23.3)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Behavior</td>
<td align="center">402</td>
<td align="center">17.8 (13.4)</td>
<td align="center">17.1 (11.0)</td>
<td align="center">16.3 (12.0)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">FAS</td>
<td align="center">424</td>
<td align="center">29.4 (5.3)</td>
<td align="center">30.0 (5.9)</td>
<td align="center">30.7 (6.0)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">IS</td>
<td align="center">425</td>
<td align="center">84.3 (15.2)</td>
<td align="center">83.0 (16.7)</td>
<td align="center">81.1 (16.4)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">TFC</td>
<td align="center">438</td>
<td align="center">9.4 (3.4)</td>
<td align="center">9.3 (3.4)</td>
<td align="center">8.8 (3.6)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">L Fluency 1‚Äô</td>
<td align="center">340</td>
<td align="center">22.7 (12.9)</td>
<td align="center">20.0 (12.6)</td>
<td align="center">19.7 (13.1)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">L Fluency 2‚Äô</td>
<td align="center">350</td>
<td align="center">33.3 (21.4)</td>
<td align="center">28.8 (19.9)</td>
<td align="center">28.2 (20.6)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Stroop W</td>
<td align="center">364</td>
<td align="center">64.4 (24.9)</td>
<td align="center">61.9 (23.3)</td>
<td align="center">65.4 (27.5)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Stroop C</td>
<td align="center">365</td>
<td align="center">47.8 (20.6)</td>
<td align="center">43.8 (17.1)</td>
<td align="center">46.7 (20.7)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">Stroop W/C</td>
<td align="center">362</td>
<td align="center">25.8 (14.3)</td>
<td align="center">23.6 (12.8)</td>
<td align="center">23.6 (15.4)</td>
<td align="center">Ns</td>
</tr>
<tr>
<td align="left">SDMT</td>
<td align="center">314</td>
<td align="center">26.6 (16.6)</td>
<td align="center">24.1 (15.2)</td>
<td align="center">25.1 (17.3)</td>
<td align="center">Ns</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>HD: Huntington‚Äôs disease; BMI: body mass index; CAG repeats refers to the number of CAGs in the mutated (<italic>mHtt</italic>) and non-mutated (normal <italic>Htt</italic>) alleles of the Huntingtin gene; UHDRS: Unified Huntington‚Äôs Disease Rating Scale; TMS: Total Motor Score; FAS: Functional Assessment Scale; IS: Independence Scale; TFC: Total Functional Capacity; Letter fluency (L Fluency) was tested with PRV letters (French norms) at 1 minute (1‚Äô) and 2 minutes (2‚Äô); Stroop C: Color; W: Word; W/C: Word/Color (interference score); SDMT: Symbol Digit Modalities Test. N: Number of patients for each variable where the data were available. Quantitative variables are presented as means, with the standard deviation in brackets, and qualitative variables are presented as frequency counts. Medication use is expressed as a percentage.</p></fn>
<fn id="t002fn002"><p>*Non corrected <italic>P</italic>-values; Chi-squared test for qualitative variables and one-way ANOVA for quantitative data; Ns: not significant.</p></fn>
</table-wrap-foot>
</table-wrap>
<sec id="sec011">
<title>Number of CAG repeats and age at onset</title>
<p>The number of CAG repeats explains 49.61% of the variability of age at onset (Œ≤ coefficient = -2.07 (SE = 0.11), <italic>P</italic> &lt; 0.001).</p>
<p>The ICC measuring agreement between expected age at onset by formula (1) and age at onset provided in the database is high for the whole cohort (0.71: [95% CI 0.65‚Äì0.76], <italic>P</italic> &lt; 0.0001) and in each <italic>COMT</italic> group (Met/Met ICC = 0.75 [95% CI 0.64‚Äì0.83], <italic>P</italic> &lt; 0.0001, Met/Val ICC = 0.70 [95% CI 0.62‚Äì0.77], <italic>P</italic> &lt; 0.0001 and Val/Val ICC = 0.66 [95% CI: 0.54‚Äì0.76], <italic>P</italic> &lt; 0.0001) (<xref ref-type="fig" rid="pone.0161106.g002">Fig 2</xref>).</p>
<fig id="pone.0161106.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Concordance between predicted and real age at onset.</title>
<p>Each point represents an individual patient. The observed age at onset is the one provided in the database. The predicted age at onset is the one calculated by the formula 21.54 + exp(9.556‚Äì0.146 x CAG). The gray line is the first bisector corresponding to the line of predicted = observed. The closeness of the points to the gray line indicates the extent to which predicted age at onset matches real age at onset. If predicted age at onset is greater than the observed age at onset, the points are located above the gray line. By contrast, if the predicted age at onset is below the real age at onset, the points are located below the gray line.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.g002" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec012">
<title>Longitudinal analysis of disease progression</title>
<p><xref ref-type="table" rid="pone.0161106.t003">Table 3</xref> displays the modeling parameters of the linear mixed models corresponding to the disease evolution within the four domains: motor, behavior, functional and cognitive. After correcting <italic>P</italic>-values, there is no effect of <italic>COMT</italic> polymorphism or the number of CAG repeats on latent processes at time 0 (estimated onset). A higher education level is correlated with higher performance in cognitive and functional domains. Gender influences the disease evolution. Men were behaviorally less impaired than women at onset. In addition, men decline more slowly than women in both the motor and cognitive domains. For all <italic>COMT</italic> polymorphism, performance declined over time for the motor, cognitive, and functional domains but not for behavior (see <xref ref-type="fig" rid="pone.0161106.g003">Fig 3</xref>). Higher number of CAG repeats is associated with a faster decline for motor, cognitive and functional domains. Met/Met HD gene carriers decline faster than Val/Val and Met/Val HD gene carriers in the cognitive domain. Met/Val HD gene carriers decline faster than Val/Val HD gene carriers in the motor domain while not differing from the Met/Met group. At age at onset and over the 10 years following disease onset, Met/Met HD gene carriers outperform Met/Val and Val/Val HD gene carriers in the cognitive domain. However, since they decline faster they subsequently perform less well than the other HD gene carriers (<xref ref-type="fig" rid="pone.0161106.g003">Fig 3</xref> and <xref ref-type="fig" rid="pone.0161106.g004">Fig 4</xref>). The intersection of the progression curves for the Met/Met and Met/Val groups is estimated at 7.2 years for the cognitive domain. The intersection of the Met/Met and Val/Val curves is estimated at 10.9 years for the cognitive domain. The intersection of the Met/Val and Val/Val curves is estimated at 11.0 years for the motor domain.</p>
<fig id="pone.0161106.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Curves of the impact of <italic>COMT</italic> polymorphism on the motor, behavioral, functional and cognitive domains, in a modeled cohort of a woman HD patients with 45 CAG repeats and 12-year education level.</title>
<p>We plotted the evolution of performance as a function of time for each task. Performance decrease was represented by a negative slope. 45 CAG repeats is the mean number in the cohort studied. The latent motor process was modeled using the UHDRS motor score; the latent behavioral process was modeled using the UHDRS behavioral score; the latent functional process was modeled using the FAS and IS scores; The latent cognitive process was modeled using letter fluency at 1 minute, letter fluency at 2 minutes, SDMT, Stroop Color, Stroop Word and Stroop Word/Color interference.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.g003" xlink:type="simple"/>
</fig>
<fig id="pone.0161106.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Curves of the impact of <italic>COMT</italic> polymorphism on each UHDRS score, in a modeled cohort of a female HD patient with 45 CAG repeats and 12-year education level.</title>
<p>We plotted the evolution of performance for each task. 45 CAG repeats is the mean number in the cohort studied. UHDRS motor score <bold>(A)</bold>; UHDRS behavioral <bold>(B)</bold>, IS: Independence Score <bold>(C)</bold>; FAS: Functional Assessment Scale <bold>(D)</bold>, cognitive (letter fluency 1‚Äô: at 1 minute <bold>(E)</bold>; letter fluency 2‚Äô: at 2 minutes <bold>(F)</bold>; SDMT: symbol digit modalities test <bold>(G)</bold>; Stroop C: Stroop color <bold>(H)</bold>; Stroop W: Stroop word <bold>(I)</bold>; Stroop W/C: Stroop interference <bold>(J</bold>).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.g004" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0161106.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.t003</object-id>
<label>Table 3</label> <caption><title>Impact of <italic>COMT</italic> genotype and the number of CAG repeats in the long allele on disease evolution within the four domains.</title></caption>
<alternatives>
<graphic id="pone.0161106.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Domains</th>
<th align="center">Motor</th>
<th align="center">(N = 348)</th>
<th align="center">Behavior</th>
<th align="center">(N = 348)</th>
<th align="center">Functional</th>
<th align="center">(N = 348)</th>
<th align="center">Cognitive</th>
<th align="center">(N = 344)</th>
</tr>
<tr>
<th align="center"/>
<th align="center">Estimate</th>
<th align="center"><italic>P</italic></th>
<th align="center">Estimate</th>
<th align="center"><italic>P</italic></th>
<th align="center">Estimate</th>
<th align="center"><italic>P</italic></th>
<th align="center">Estimate</th>
<th align="center"><italic>P</italic></th>
</tr>
<tr>
<th align="left"/>
<th align="center">(SE)</th>
<th align="center">(Corrected <italic>P</italic>)</th>
<th align="center">(SE)</th>
<th align="center">(Corrected <italic>P</italic>)</th>
<th align="center">(SE)</th>
<th align="center">(Corrected <italic>P</italic>)</th>
<th align="center">(SE)</th>
<th align="center">(Corrected <italic>P</italic>)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Baseline:</bold></td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left" rowspan="2">Met/Val vs Met/Met</td>
<td align="center">0.08</td>
<td align="center">0.6595</td>
<td align="center">-0.39</td>
<td align="center">0.1592</td>
<td align="center">-0.10</td>
<td align="center">0.5478</td>
<td align="center">-0.30</td>
<td align="center">0.0521</td>
</tr>
<tr>
<td align="center">(0.18)</td>
<td align="center">(ns)</td>
<td align="center">(0.28)</td>
<td align="center">(ns)</td>
<td align="center">(0.17)</td>
<td align="center">(ns)</td>
<td align="center">(0.16)</td>
<td align="center">(ns)</td>
</tr>
<tr>
<td align="left" rowspan="2">Val/Val vs Met/Met</td>
<td align="center">-0.26</td>
<td align="center">0.1825</td>
<td align="center">-0.18</td>
<td align="center">0.5427</td>
<td align="center">-0.19</td>
<td align="center">0.3105</td>
<td align="center">-0.37</td>
<td align="center">0.0344*</td>
</tr>
<tr>
<td align="center">(0.20)</td>
<td align="center">(ns)</td>
<td align="center">(0.30)</td>
<td align="center">(ns)</td>
<td align="center">(0.19)</td>
<td align="center">(ns)</td>
<td align="center">(0.17)</td>
<td align="center">(ns)</td>
</tr>
<tr>
<td align="left" rowspan="2">Val/Val vs Met/Val</td>
<td align="center">-0.34</td>
<td align="center">0.0383*</td>
<td align="center">0.21</td>
<td align="center">0.3708</td>
<td align="center">-0.09</td>
<td align="center">0.5654</td>
<td align="center">-0.06</td>
<td align="center">0.6605</td>
</tr>
<tr>
<td align="center">(0.16)</td>
<td align="center">(ns)</td>
<td align="center">(0.23)</td>
<td align="center">(ns)</td>
<td align="center">(0.16)</td>
<td align="center">(ns)</td>
<td align="center">(0.15)</td>
<td align="center">(ns)</td>
</tr>
<tr>
<td align="left" rowspan="2">Number of CAG repeats</td>
<td align="center">-0.01</td>
<td align="center">0.4087</td>
<td align="center">0.07</td>
<td align="center">0.1202</td>
<td align="center">0.04</td>
<td align="center">0.0391*</td>
<td align="center">0.03</td>
<td align="center">0.0443*</td>
</tr>
<tr>
<td align="center">(0.02)</td>
<td align="center">(ns)</td>
<td align="center">(0.04)</td>
<td align="center">(ns)</td>
<td align="center">(0.02)</td>
<td align="center">(ns)</td>
<td align="center">(0.02)</td>
<td align="center">(ns)</td>
</tr>
<tr>
<td align="left" rowspan="2">Education level</td>
<td align="center">0.04</td>
<td align="center">0.0500</td>
<td align="center">0.05</td>
<td align="center">0.0181*</td>
<td align="center">0.06</td>
<td align="center">0.0014**</td>
<td align="center">0.08</td>
<td align="center">&lt;0.0001***</td>
</tr>
<tr>
<td align="center">(0.02)</td>
<td align="center">(ns)</td>
<td align="center">(0.02)</td>
<td align="center">(ns)</td>
<td align="center">(0.02)</td>
<td align="center">(0.0056**)</td>
<td align="center">(0.02)</td>
<td align="center">(0.0001***)</td>
</tr>
<tr>
<td align="left" rowspan="2">Gender Man vs Woman</td>
<td align="center">-0.04</td>
<td align="center">0.7566</td>
<td align="center">0.54</td>
<td align="center">0.0082**</td>
<td align="center">0.30</td>
<td align="center">0.0233*</td>
<td align="center">-0.04</td>
<td align="center">0.7436</td>
</tr>
<tr>
<td align="center">(0.14)</td>
<td align="center">(ns)</td>
<td align="center">(0.20)</td>
<td align="center">(0.0328*)</td>
<td align="center">(0.13)</td>
<td align="center">(ns)</td>
<td align="center">(0.12)</td>
<td align="center">(ns)</td>
</tr>
<tr>
<td align="left"><bold>Slope:</bold></td>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="left" rowspan="2">Met/Val vs Met/Met</td>
<td align="center">-0.01</td>
<td align="center">0.3671</td>
<td align="center">0.06</td>
<td align="center">0.0171*</td>
<td align="center">0.02</td>
<td align="center">0.1339</td>
<td align="center">0.04</td>
<td align="center">&lt;0.0001***</td>
</tr>
<tr>
<td align="center">(0.01)</td>
<td align="center">(ns)</td>
<td align="center">(0.02)</td>
<td align="center">(ns)</td>
<td align="center">(0.01)</td>
<td align="center">(ns)</td>
<td align="center">(0.01)</td>
<td align="center">(&lt;0.0001***)</td>
</tr>
<tr>
<td align="left" rowspan="2">Val/Val vs Met/Met</td>
<td align="center">0.02</td>
<td align="center">0.1160</td>
<td align="center">0.03</td>
<td align="center">0.2961</td>
<td align="center">0.01</td>
<td align="center">0.4642</td>
<td align="center">0.03</td>
<td align="center">0.0002***</td>
</tr>
<tr>
<td align="center">(0.01)</td>
<td align="center">(ns)</td>
<td align="center">(0.03)</td>
<td align="center">(ns)</td>
<td align="center">(0.01)</td>
<td align="center">(ns)</td>
<td align="center">(0.01)</td>
<td align="center">(0.0012**)</td>
</tr>
<tr>
<td align="left" rowspan="2">Val/Val vs Met/Val</td>
<td align="center">0.03</td>
<td align="center">0.0044**</td>
<td align="center">-0.03</td>
<td align="center">0.1711</td>
<td align="center">-0.01</td>
<td align="center">0.4700</td>
<td align="center">-0.01</td>
<td align="center">0.2221</td>
</tr>
<tr>
<td align="center">(0.01)</td>
<td align="center">(0.0264*)</td>
<td align="center">(0.02)</td>
<td align="center">(ns)</td>
<td align="center">(0.01)</td>
<td align="center">(ns)</td>
<td align="center">(0.01)</td>
<td align="center">(ns)</td>
</tr>
<tr>
<td align="left" rowspan="2">Number of CAG repeats</td>
<td align="center">-0.01</td>
<td align="center">&lt;0.0001***</td>
<td align="center">-0.01</td>
<td align="center">0.0953</td>
<td align="center">-0.01</td>
<td align="center">&lt;0.0001***</td>
<td align="center">-0.01</td>
<td align="center">&lt;0.0001***</td>
</tr>
<tr>
<td align="center">(0.001)</td>
<td align="center">(&lt;0.0001)</td>
<td align="center">(0.004)</td>
<td align="center">(ns)</td>
<td align="center">(0.001)</td>
<td align="center">(&lt;0.0001***)</td>
<td align="center">(0.001)</td>
<td align="center">(&lt;0.0001***)</td>
</tr>
<tr>
<td align="left" rowspan="2">Gender Man vs Woman</td>
<td align="center">0.03</td>
<td align="center">0.0016**</td>
<td align="center">-0.06</td>
<td align="center">0.0042**</td>
<td align="center">-0.01</td>
<td align="center">0.3862</td>
<td align="center">0.02</td>
<td align="center">0.0020**</td>
</tr>
<tr>
<td align="center">(0.01)</td>
<td align="center">(0.0064**)</td>
<td align="center">(0.02)</td>
<td align="center">(0.0168*)</td>
<td align="center">(0.01)</td>
<td align="center">(ns)</td>
<td align="center">(0.01)</td>
<td align="center">(0.0080**)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>The motor domain was modeled including the performances at TMS; the behavioral domain was modeled including the performances at behavior task of the UHDRS; the functional domain was modeled including the performances at FAS and IS (TFC could not be included because there are not enough values for the model to converge); the cognitive domain was modeled including performances at letter fluency assessed at 1 and 2 minutes, SDMT and the three parts of the Stroop.</p></fn>
<fn id="t003fn002"><p>N: Number of HD gene carriers who have contributed to the estimation (cognitive tasks were not available for all HD gene carriers); SE: Standard error of the estimate</p></fn>
<fn id="t003fn003"><p><italic>P</italic>: <italic>P</italic>-values (*** P&lt;0.001, ** P&lt;0.01, *P&lt;0.05).</p></fn>
<fn id="t003fn004"><p><italic>Baseline</italic> values correspond to the impact of covariates at estimated age at onset. <italic>Slope</italic> values correspond to the impact of covariates on the slope of the decline.</p></fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="fig" rid="pone.0161106.g004">Fig 4</xref> shows that for most tasks, the fit of disease is linear only for the first 15 years, displaying a floor effect after that point. Beta link functions between performance at each task and latent variable modeling of the domains are displayed in <xref ref-type="supplementary-material" rid="pone.0161106.s003">S3 Fig</xref>.</p>
<p>In the sensitivity analysis, larger number of CAG repeats is associated with a faster decline over time, in all domains except behavior. Met/Val HD gene carriers decline faster than Val/Val HD gene carriers in motor domain. Met/Met HD gene carriers decline faster than Val/Val and Met/Val HD gene carriers in cognitive domain, but the associated <italic>P</italic>-value is no longer significant after Bonferroni correction (see <xref ref-type="supplementary-material" rid="pone.0161106.s005">S2 Table</xref>).</p>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>We investigated the impact of <italic>COMT</italic> polymorphism in a prospective multicentre study of 438 HD gene carriers at all stages of HD, from which 350, with identified age of onset, were followed up once a year with the UHDRS during 4.8 (SD = 2.9) years. The <italic>COMT</italic> polymorphism distribution in this sample is similar to that reported for the European population [<xref ref-type="bibr" rid="pone.0161106.ref039">39</xref>]. As previously reported, the number of CAG repeats affects the age at onset and the disease progression in our cohort [<xref ref-type="bibr" rid="pone.0161106.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0161106.ref009">9</xref>]. Higher educational level improves cognitive performance at baseline, as observed in elderly populations [<xref ref-type="bibr" rid="pone.0161106.ref040">40</xref>]. We show that <italic>COMT</italic> polymorphism influences disease progression in a biphasic way in the cognitive and motor domains, and tends to influence the functional domain as well. Met/Met HD gene carriers outperform Val/Val HD gene carriers in the cognitive during the first 10 years after disease onset. However, since the slope of decline is steeper in the Met/Met HD gene carriers, they then performed worse than Val/Val HD gene carriers. The effect of <italic>COMT</italic> polymorphism is of particular interest because, in contrast to other genetic modulations previously reported, this polymorphism affects progression rather than age at onset [<xref ref-type="bibr" rid="pone.0161106.ref002">2</xref>, <xref ref-type="bibr" rid="pone.0161106.ref004">4</xref>].</p>
<p>This study replicates the effect of the number of CAG repeats observed in other studies [<xref ref-type="bibr" rid="pone.0161106.ref041">41</xref>, <xref ref-type="bibr" rid="pone.0161106.ref042">42</xref>]. It allows deciphering the effect of <italic>COMT</italic> polymorphism presumably because unlike previous studies on other cohorts [<xref ref-type="bibr" rid="pone.0161106.ref043">43</xref>], we did not select HD gene carriers at particular disease stages or with a specific number of CAG repeats. In addition we improved the value of our results by selecting the number of CAG repeats without including the age at onset as a covariate despite its known value [<xref ref-type="bibr" rid="pone.0161106.ref008">8</xref>] to avoid redundancy [<xref ref-type="bibr" rid="pone.0161106.ref044">44</xref>] since the age at onset and the number of CAG repeats are two correlated factors [<xref ref-type="bibr" rid="pone.0161106.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0161106.ref033">33</xref>]. Furthermore, the use of a single language for cognitive testing decreased inter-subject variability in cognitive performance. The HD gene carriers were followed up prospectively for as long as possible, from pre-manifest to advanced stages. Although most of the data was collected between 5 and 15 years after disease onset, it provides a unique continuum of disease progression with enough follow up data to conduct a longitudinal analysis. Results of the sensitivity analysis displayed the same trend as the analysis of the whole sample, however without reaching significance after Bonferroni correction for multiple testing.</p>
<p>The latent-class mixed model has the advantage of grouping several tasks within domains and provides a global picture by domain without focusing on specific tasks. This approach, recently developed, is already used in studies evaluating cognitive decline [<xref ref-type="bibr" rid="pone.0161106.ref045">45</xref>, <xref ref-type="bibr" rid="pone.0161106.ref046">46</xref>]. To ensure that it models disease progression as well as the classical task by task multiple linear mixed model [<xref ref-type="bibr" rid="pone.0161106.ref047">47</xref>, <xref ref-type="bibr" rid="pone.0161106.ref048">48</xref>], we ran both latent-class mixed models and the linear mixed models on our data (see <xref ref-type="supplementary-material" rid="pone.0161106.s006">S3 Table</xref>). Both models show higher cognitive decline for the Met/Met group. The latent-mixed model has also the advantage of avoiding the calculation of sum of performance for tasks with different weights and to take into account all assessments, and not only a delta between baseline and last assessment, as in some regression linear analyses [<xref ref-type="bibr" rid="pone.0161106.ref049">49</xref>].</p>
<p>Our study shows that the impact of <italic>COMT</italic> polymorphism differs according to each domain like in previous studies of Parkinson‚Äôs disease and schizophrenia [<xref ref-type="bibr" rid="pone.0161106.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0161106.ref020">20</xref>, <xref ref-type="bibr" rid="pone.0161106.ref050">50</xref>]. The effect of <italic>COMT</italic> polymorphism was observed in the cognitive and motor domains but not in the behavioral and functional domains. However, the pattern was similar in the motor, cognitive and functional domains, without reaching significance in the latter. The Val/Val group show a less steep progression than the Met/Met group in the cognitive domain, and than the Met/Val group in the motor domain. The lack of significance in the functional domain presumably relies on the smaller range of performance in this domain than in the motor and cognitive domains. It is worth noting that in contrast, the behavioral score does not show any decline overtime in HD.</p>
<p>The impact of <italic>COMT</italic> polymorphism on cognitive functions is of particular interest because the cognitive abilities are the major cause of social withdrawal in HD. Executive functions are modulated by <italic>COMT</italic> polymorphism, and improve along with the increase of DA availability, as observed in healthy individuals with the Met/Met genotype [<xref ref-type="bibr" rid="pone.0161106.ref051">51</xref>]. DA in the striatum has phasic variations and affects executive tasks requiring cognitive flexibility and switching between object features, such as in the Wisconsin Card Sorting Test and attention set-shifting test [<xref ref-type="bibr" rid="pone.0161106.ref052">52</xref>]. In the PFC, DA availability is more tonic and modulates the ability to maintain information as required in selective attention or working memory [<xref ref-type="bibr" rid="pone.0161106.ref053">53</xref>, <xref ref-type="bibr" rid="pone.0161106.ref054">54</xref>]. The tasks we used here fall into this latter category presumably taping the PFC.</p>
<p>These effects on disease progression have implications for our understanding of the dynamics of DA in the PFC and striatum in HD. <italic>COMT</italic> influences DA levels, mostly in the PFC, consistent with the specific effect on cognitive symptoms observed in HD. Indeed, DA antagonists with systemic action, which reduce DA levels in both the PFC and striatum, have been shown to worsen cognitive impairment [<xref ref-type="bibr" rid="pone.0161106.ref027">27</xref>] and chorea intensity at early stages. As in healthy individuals [<xref ref-type="bibr" rid="pone.0161106.ref022">22</xref>], the higher availability of DA in the Met/Met genotype is associated with a preservation of cognitive function at early stages. The greater availability of DA in Met/Met individuals appears to have an effect similar to cognitive reserve in the initial stages of the disease. The effects of high DA levels, which are initially beneficial in the early stages of the disease, eventually become detrimental, due to the long-term toxicity of DA in striatal cells [<xref ref-type="bibr" rid="pone.0161106.ref026">26</xref>].</p>
<p>This biphasic pattern over time suggests a symptomatic, rather than neuroprotective effect. Consistently, early and chronic treatment with the D2 antagonist haloperidol decanoate protects against neuronal dysfunction and aggregate formation in a rat model of HD [<xref ref-type="bibr" rid="pone.0161106.ref055">55</xref>]. <italic>COMT</italic> polymorphism also determines the response to entacapone [<xref ref-type="bibr" rid="pone.0161106.ref029">29</xref>] but not to levodopa. Considering the similar trend of evolution in the cognitive, motor and functional domains, we cannot rule out the possibility of the Val allele being neuroprotective <italic>per se</italic>, since Met/Met individuals display greater gray matter degeneration within DA-innervated structures, including the striatum [<xref ref-type="bibr" rid="pone.0161106.ref051">51</xref>].</p>
<p>These results open up new possibilities for treatments tailored to patient genotype, slowing disease progression, especially for treatments controlling cognitive function decline, which are currently lacking. It should pave the way for personalized treatment in HD gene carriers by adapting treatment to time- and region-specific changes, taking <italic>COMT</italic> genotype into account. At early stages of the disease, the combination of treatments decreasing DA levels in the striatum and <italic>COMT</italic> inhibitors increasing DA levels in the PFC, might prevent the exacerbation of cognitive deficits, or even improve cognitive ability (<xref ref-type="fig" rid="pone.0161106.g005">Fig 5</xref>) in Val/Val HD gene carriers. It has an immediate application in pharmacological management of HD, as inhibitors or activators of <italic>COMT</italic> are already available. At later stages, more than 10 years after onset, it may be harder to target DA levels in the PFC specifically, as classical antipsychotic drugs occupy a large proportion of subcortical dopamine D2 receptors, whereas atypical antipsychotics preferentially occupy cortical 5-HT(2) receptors.</p>
<fig id="pone.0161106.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0161106.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Schematic representation of the biphasic effect of <italic>COMT</italic> polymorphism in HD.</title>
<p>In the prefrontal cortex, DA levels are higher in Met/Met HD gene carriers at early stages and in HD gene carriers with premanifest disease than in controls. These levels subsequently decrease over time in both the Met/Met (in blue) and Val/Val groups (in red) [<xref ref-type="bibr" rid="pone.0161106.ref056">56</xref>]. The high levels of DA present in the PFC at early stages result in better cognitive performances. At late stages, higher levels of DA in the PFC in Met/Met HD gene carriers may be toxic, increasing atrophy [<xref ref-type="bibr" rid="pone.0161106.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0161106.ref051">51</xref>]. In both <italic>COMT</italic> groups, the level of striatal DA decreases over time.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.g005" xlink:type="simple"/>
</fig>
<p>Our study also has practical implications for future clinical trials assessing decline in HD because <italic>COMT</italic> polymorphism appears as an important factor of stratification. Moreover, the methodology we used could be adapted to other neurodegenerative diseases.</p>
</sec>
<sec id="sec014">
<title>Supporting Information</title>
<supplementary-material id="pone.0161106.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Distribution of CAG repeats length in the database.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0161106.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Repartition of stages in time according to <italic>COMT</italic> polymorphisms.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0161106.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Link functions between performances at each task and latent processes modelling the domains.</title>
<p>We plotted the link function between each task and latent domains. UHDRS motor score <bold>(A)</bold>; UHDRS behavioral <bold>(B)</bold>, IS: Independence Score <bold>(C)</bold>; FAS: Functional Assessment Scale <bold>(D)</bold>, cognitive (letter fluency 1‚Äô: at 1 minute <bold>(E)</bold>; letter fluency 2‚Äô: at 2 minutes <bold>(F)</bold>; SDMT: symbol digit modalities test <bold>(G)</bold>; Stroop C: Stroop color <bold>(H)</bold>; Stroop W: Stroop word <bold>(I)</bold>; Stroop W/C: Stroop interference <bold>(J</bold>).</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0161106.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.s004" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Demographic characteristics and performance of HD gene carriers including in the longitudinal analysis (N = 350).</title>
<p>HD: Huntington‚Äôs disease; BMI: body mass index; CAG repeats refers to the number of CAGs in the mutated (<italic>mHtt</italic>) and non-mutated (normal <italic>Htt</italic>) alleles of the Huntingtin gene; UHDRS: Unified Huntington‚Äôs Disease Rating Scale; TMS: Total Motor Score; FAS: Functional Assessment Scale; IS: Independence Scale; TFC: Total Functional Capacity; Letter fluency (L Fluency) was tested with PRV letters (French norms) at 1 minute (1‚Äô) and 2 minutes (2‚Äô); Stroop C: Color; W: Word; W/C: Word/Color (interference score); SDMT: Symbol Digit Modalities Test. Quantitative variables are presented as means, with the standard deviation in brackets, and qualitative variables are presented as frequency counts. Medication use is expressed as a percentage.*Non corrected <italic>P</italic>-values; Chi-squared test for qualitative variables and one-way ANOVA for quantitative data; Ns: not significant.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0161106.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.s005" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Modelling results of the sensitivity analysis excluding outliers.</title>
<p>The motor domain was modeled including the performances in the TMS; the behavioral domain was modeled including the performances at behavior task of the UHDRS; the functional domain was modeled including the performances at FAS and IS (TFC could not be included because there are not enough values for the model to converge); the cognitive domain was modeled including performances at letter fluency assessed at 1 and 2 minutes, SDMT and the three parts of the Stroop. N: Number of HD gene carriers who have contributed to the estimation (cognitive tasks were not available for all HD gene carriers); SE: Standard error of the estimate, <italic>P</italic>: <italic>P</italic>-values (*** P&lt;0.001, ** P&lt;0.01, *P&lt;0.05). <italic>Baseline</italic> values correspond to the impact of covariates at estimated age at onset. <italic>Slope</italic> values correspond to the impact of covariates on the slope of the decline.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0161106.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0161106.s006" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Modelling results of linear mixed models for each tasks.</title>
<p>TMS: Total motor score, IS: Independence Scale, FAS: Functional Assessment Scale, SDMT: Symbol Digit Modalities Test, Stroop C: Stroop Color, Stroop W: Stroop Word, Stroop W/C: Stroop interference. N: Number of HD gene carriers who have contributed to the estimation (cognitive tasks were not available for all HD gene carriers); SE: Standard error of the estimate, <italic>P</italic>: <italic>P</italic>-values (*** P&lt;0.001, ** P&lt;0.01, *P&lt;0.05). <italic>Baseline</italic> values correspond to the impact of covariates at estimated age at onset. <italic>Slope</italic> values correspond to the impact of covariates on the slope of the decline.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank C. Lalanne for comments relating to methodology and Page Piccinini for her language corrections.</p>
<p>The French Speaking Huntington group is leaded by AC Bachoud-L√©vi at the national reference centre for Huntington‚Äôs disease. Contributors: Angers: G. Aubin, A Olivier, P Allain; Bordeaux: U Spampinato, S Debruxelles, B Babiloni, C Duch√©; Cr√©teil: M-F Boiss√©, M Couette, L Lemoine, S Baudic, G Morgado; Lille: P Krystkowiak, M Delliaux, K Dujardin; Lyon: H Mollion, E Broussolle; Paris: V Hahn-Barma; Strasbourg: N Longato, G Rudolf.</p>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>CAG</term>
<def><p>Cytosine-Adenine-Guanine</p></def>
</def-item>
<def-item><term><italic>COMT</italic></term>
<def><p><italic>Catechol-O-Methyltransferase</italic></p></def>
</def-item>
<def-item><term>DA</term>
<def><p>Dopamine</p></def>
</def-item>
<def-item><term>FAS</term>
<def><p>Functional Assessment Scale</p></def>
</def-item>
<def-item><term>HD</term>
<def><p>Huntington‚Äôs disease</p></def>
</def-item>
<def-item><term>Htt</term>
<def><p>Huntingtin</p></def>
</def-item>
<def-item><term>ICC</term>
<def><p>Intraclass Correlation Coefficient</p></def>
</def-item>
<def-item><term>IS</term>
<def><p>Independence Scale</p></def>
</def-item>
<def-item><term>Met</term>
<def><p>Methionine</p></def>
</def-item>
<def-item><term>mHtt</term>
<def><p>Mutant Huntingtin</p></def>
</def-item>
<def-item><term>PFC</term>
<def><p>Prefrontal Cortex</p></def>
</def-item>
<def-item><term>SD</term>
<def><p>Standard Deviation</p></def>
</def-item>
<def-item><term>SDMT</term>
<def><p>Symbol Digit Modalities Score</p></def>
</def-item>
<def-item><term>SE</term>
<def><p>Standard Error</p></def>
</def-item>
<def-item><term>TFC</term>
<def><p>Total Function Capacity</p></def>
</def-item>
<def-item><term>UHDRS</term>
<def><p>Unified Huntington‚Äôs Disease Rating Scale</p></def>
</def-item>
<def-item><term>Val</term>
<def><p>Valine</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pone.0161106.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>The Huntington Collaborative Study Group</collab>. <article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington‚Äôs disease chromosomes</article-title>. <source>Cell</source>. <year>1993</year>;<volume>72</volume>: <fpage>971</fpage>‚Äì<lpage>983</lpage>. <object-id pub-id-type="pmid">8458085</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wexler</surname> <given-names>NS</given-names></name>. <article-title>Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington‚Äôs disease age of onset</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2004</year>;<volume>10</volume>: <fpage>3498</fpage>‚Äì<lpage>3503</lpage>.</mixed-citation></ref>
<ref id="pone.0161106.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee J-</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ramos</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Lee J-</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Gillis</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mysore</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Hayden</surname> <given-names>MR</given-names></name>, <etal>et al</etal>. <article-title>CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion</article-title>. <source>Neurology</source>. <year>2012</year>;<volume>78</volume>: <fpage>690</fpage>‚Äì<lpage>695</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0b013e318249f683" xlink:type="simple">10.1212/WNL.0b013e318249f683</ext-link></comment> <object-id pub-id-type="pmid">22323755</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ramos</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Latourelle</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Gillis</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mysore</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Squitieri</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Di Pardo</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington‚Äôs disease motor onset</article-title>. <source>Neurogenetics</source>. <year>2013</year>;<volume>14</volume>: <fpage>173</fpage>‚Äì<lpage>179</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10048-013-0364-y" xlink:type="simple">10.1007/s10048-013-0364-y</ext-link></comment> <object-id pub-id-type="pmid">23644918</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arning</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Epplen</surname> <given-names>JT</given-names></name>. <article-title>Genetic modifiers in Huntington‚Äôs disease: fiction or fact</article-title>? <source>Neurogenetics</source>. <year>2013</year>;<volume>14</volume>: <fpage>171</fpage>‚Äì<lpage>172</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10048-013-0365-x" xlink:type="simple">10.1007/s10048-013-0365-x</ext-link></comment> <object-id pub-id-type="pmid">23754186</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gusella</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>MacDonald</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>J-M</given-names></name>. <article-title>Genetic modifiers of Huntington‚Äôs disease</article-title>. <source>Mov Disord</source>. <year>2014</year>;<volume>29</volume>: <fpage>1359</fpage>‚Äì<lpage>1365</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.26001" xlink:type="simple">10.1002/mds.26001</ext-link></comment> <object-id pub-id-type="pmid">25154728</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ross</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Tabrizi</surname> <given-names>SJ</given-names></name>. <article-title>Huntington‚Äôs disease: from molecular pathogenesis to clinical treatment</article-title>. <source>Lancet Neurol</source>. Elsevier Ltd; <year>2011</year>;<volume>10</volume>: <fpage>83</fpage>‚Äì<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(10)70245-3" xlink:type="simple">10.1016/S1474-4422(10)70245-3</ext-link></comment> <object-id pub-id-type="pmid">21163446</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenblatt</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kumar B</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Mo</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Welsh</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Margolis</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Ross C</surname> <given-names>A</given-names></name>. <article-title>Age, CAG repeat length, and clinical progression in Huntington‚Äôs disease</article-title>. <source>Mov Disord</source>. <year>2012</year>;<volume>27</volume>: <fpage>272</fpage>‚Äì<lpage>276</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.24024" xlink:type="simple">10.1002/mds.24024</ext-link></comment> <object-id pub-id-type="pmid">22173986</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aziz</surname> <given-names>NA</given-names></name>, <name name-style="western"><surname>Jurgens</surname> <given-names>CK</given-names></name>, <name name-style="western"><surname>Landwehrmeyer</surname> <given-names>GB</given-names></name>, <name name-style="western"><surname>Van Roon-Mom</surname> <given-names>WMC</given-names></name>, <name name-style="western"><surname>Van Ommen</surname> <given-names>GJB</given-names></name>, <name name-style="western"><surname>Stijnen</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease</article-title>. <source>Neurology</source>. <year>2009</year>;<volume>73</volume>: <fpage>1280</fpage>‚Äì<lpage>1285</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0b013e3181bd1121" xlink:type="simple">10.1212/WNL.0b013e3181bd1121</ext-link></comment> <object-id pub-id-type="pmid">19776381</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Wheeler</surname> <given-names>VC</given-names></name>, <name name-style="western"><surname>Chao</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Vonsattel</surname> <given-names>JPG</given-names></name>, <name name-style="western"><surname>Pinto</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Lucente</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Identification of genetic factors that modify clinical onset of Huntington‚Äôs disease</article-title>. <source>Cell</source>. <year>2015</year>;<volume>162</volume>(<issue>3</issue>): <fpage>516</fpage>‚Äì<lpage>526</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.07.003" xlink:type="simple">10.1016/j.cell.2015.07.003</ext-link></comment> <object-id pub-id-type="pmid">26232222</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beƒçanoviƒá</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>N√∏rrem√∏lle</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Neal</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kay</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Collins</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Arenillas</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>A SNP in the HTT promoter alters NF-[kappa] B binding and is a bidirectional genetic modifier of Huntington disease</article-title>. <source>Nature neuroscience</source>. <year>2015</year>;<volume>18</volume>(<issue>6</issue>), <fpage>807</fpage>‚Äì<lpage>816</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn.4014" xlink:type="simple">10.1038/nn.4014</ext-link></comment> <object-id pub-id-type="pmid">25938884</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vonsattel</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>DiFiglia</surname> <given-names>M</given-names></name>. <article-title>Huntington disease</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>1998</year>;<volume>57</volume>: <fpage>369</fpage>‚Äì<lpage>384</lpage>. <object-id pub-id-type="pmid">9596408</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Turjanski</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Weeks</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Dolan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Harding</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Brooks</surname> <given-names>DJ</given-names></name>. <article-title>Striatal D 1 and D 2 receptor binding in patients with Huntington‚Äôs disease and other choreas A PET study</article-title>. <source>Brain</source>. <year>1995</year>;<volume>118</volume>: <fpage>689</fpage>‚Äì<lpage>696</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/brain/118.3.689" xlink:type="simple">10.1093/brain/118.3.689</ext-link></comment> <object-id pub-id-type="pmid">7600086</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choi</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Begeti</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>SY</given-names></name>, <name name-style="western"><surname>O'Keeffe</surname> <given-names>GC</given-names></name>, <name name-style="western"><surname>Clelland</surname> <given-names>CD</given-names></name>, <etal>et al</etal>. <article-title>Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington‚Äôs disease</article-title>. <source>Neurobiol Dis</source>. <year>2014</year>;<volume>66</volume>: <fpage>19</fpage>‚Äì<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2014.02.004" xlink:type="simple">10.1016/j.nbd.2014.02.004</ext-link></comment> <object-id pub-id-type="pmid">24561069</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pavese</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Politis</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tai</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Barker</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Tabrizi</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Mason</surname> <given-names>SL</given-names></name>, <etal>et al</etal>. <article-title>Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers</article-title>. <source>Neurobiol Dis.</source>;<volume>37</volume>(<issue>2</issue>): <fpage>356</fpage>‚Äì<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2009.10.015" xlink:type="simple">10.1016/j.nbd.2009.10.015</ext-link></comment> <object-id pub-id-type="pmid">19853661</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lipska</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Halim</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>QD</given-names></name>, <name name-style="western"><surname>Matsumoto</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Melhem</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain</article-title>. <source>Am J Hum Genet</source>. <year>2004</year>;<volume>75</volume>: <fpage>807</fpage>‚Äì<lpage>821</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/425589" xlink:type="simple">10.1086/425589</ext-link></comment> <object-id pub-id-type="pmid">15457404</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schacht</surname> <given-names>JP</given-names></name>. <article-title>COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review</article-title>. <source>The pharmacogenomics journal</source>. <year>2016</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/tpj.2016.43" xlink:type="simple">10.1038/tpj.2016.43</ext-link></comment></mixed-citation></ref>
<ref id="pone.0161106.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Foltynie</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Brayne</surname> <given-names>CEG</given-names></name>, <name name-style="western"><surname>Robbins</surname> <given-names>TW</given-names></name>, <name name-style="western"><surname>Barker</surname> <given-names>RA</given-names></name>. <article-title>The cognitive ability of an incident cohort of Parkinson‚Äôs patients in the UK. The CamPaIGN study</article-title>. <source>Brain</source>. <year>2004</year>;<volume>127</volume>: <fpage>550</fpage>‚Äì<lpage>560</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/brain/awh067" xlink:type="simple">10.1093/brain/awh067</ext-link></comment> <object-id pub-id-type="pmid">14691062</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>O‚ÄôKeeffe</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Politis</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>O‚ÄôKeeffe</surname> <given-names>GC</given-names></name>, <name name-style="western"><surname>Robbins</surname> <given-names>TW</given-names></name>, <name name-style="western"><surname>Bose</surname> <given-names>SK</given-names></name>, <etal>et al</etal>. <article-title>The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson‚Äôs disease: a PET study</article-title>. <source>Brain</source>. <year>2012</year>;<volume>135</volume>: <fpage>2449</fpage>‚Äì<lpage>2457</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/brain/aws157" xlink:type="simple">10.1093/brain/aws157</ext-link></comment> <object-id pub-id-type="pmid">22843413</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meyer-Lindenberg</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Miletich</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Kohn</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Esposito</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Carson</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Quarantelli</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia</article-title>. <source>Nat Neurosci</source>. <year>2002</year>;<volume>5</volume>: <fpage>267</fpage>‚Äì<lpage>271</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn804" xlink:type="simple">10.1038/nn804</ext-link></comment> <object-id pub-id-type="pmid">11865311</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gothelf</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Eliez</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hinard</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Penniman</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Feinstein</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome</article-title>. <source>Nat Neurosci</source>. Nature Publishing Group; <year>2005</year>;<volume>8</volume>: <fpage>1500</fpage>‚Äì<lpage>1502</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nn1572" xlink:type="simple">10.1038/nn1572</ext-link></comment> <object-id pub-id-type="pmid">16234808</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wolf</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Kl√∂ppel</surname> <given-names>S</given-names></name>. <article-title>Clinical significance of frontal cortex abnormalities in Huntington‚Äôs disease</article-title>. <source>Exp Neurol</source>. <year>2013</year>;<volume>247</volume>: <fpage>39</fpage>‚Äì<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.expneurol.2013.03.022" xlink:type="simple">10.1016/j.expneurol.2013.03.022</ext-link></comment> <object-id pub-id-type="pmid">23562669</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vinther-Jensen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nielsen</surname> <given-names>TT</given-names></name>, <name name-style="western"><surname>Budtz-J√∏rgensen</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Larsen</surname> <given-names>IU</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Hasholt</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Psychiatric and cognitive symptoms in Huntington‚Äôs disease are modified by polymorphisms in catecholamine regulating enzyme genes</article-title>. <source>Clin Genet</source>. <year>2016</year>;<volume>89</volume>(<issue>3</issue>): <fpage>320</fpage>‚Äì<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/cge.12628. Epub 2015 Jul 17" xlink:type="simple">10.1111/cge.12628. Epub 2015 Jul 17</ext-link></comment> <object-id pub-id-type="pmid">26081309</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cools</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>D‚ÄôEsposito</surname> <given-names>M</given-names></name>. <article-title>Inverted-U-shaped dopamine actions on human working memory and cognitive control</article-title>. <source>Biol Psychiatry</source>. Elsevier Inc.; <year>2011</year>;<volume>69</volume>: <fpage>e113</fpage>‚Äì<lpage>125</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.biopsych.2011.03.028" xlink:type="simple">10.1016/j.biopsych.2011.03.028</ext-link></comment> <object-id pub-id-type="pmid">21531388</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Green</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Munaf√≤</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>DeYoung</surname> <given-names>CG</given-names></name>, <name name-style="western"><surname>Fossella</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Fan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gray</surname> <given-names>JR</given-names></name>. <article-title>Using genetic data in cognitive neuroscience: from growing pains to genuine insights</article-title>. <source>Nat Rev Neurosci</source>. Nature Publishing Group; <year>2008</year>;<volume>9</volume>: <fpage>710</fpage>‚Äì<lpage>720</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrn2461" xlink:type="simple">10.1038/nrn2461</ext-link></comment> <object-id pub-id-type="pmid">19143051</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Charvin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Vanhoutte</surname> <given-names>P</given-names></name>. <article-title>Unraveling a role for dopamine in Huntington‚Äôs disease: the dual role of reactive oxygen species and D2 receptor stimulation</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2005</year>;<volume>102</volume>(<issue>34</issue>), <fpage>12218</fpage>‚Äì<lpage>12223</lpage>. <object-id pub-id-type="pmid">16103364</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname> <given-names>T-S</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bezprozvanny</surname> <given-names>I</given-names></name>. <article-title>Dopaminergic signaling and striatal neurodegeneration in Huntington‚Äôs disease</article-title>. <source>J Neurosci</source>. <year>2007</year>;<volume>27</volume>: <fpage>7899</fpage>‚Äì<lpage>7910</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1523/JNEUROSCI.1396-07.2007" xlink:type="simple">10.1523/JNEUROSCI.1396-07.2007</ext-link></comment> <object-id pub-id-type="pmid">17652581</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harbo</surname> <given-names>HF</given-names></name>, <name name-style="western"><surname>Finsterer</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Baets</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Van Broeckhoven</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Di Donato</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Fontaine</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington‚Äôs disease, Parkinson‚Äôs disease and dystonias</article-title>. <source>Eur J Neurol</source>. <year>2009</year>;<volume>16</volume>: <fpage>777</fpage>‚Äì<lpage>785</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1468-1331.2009.02646.x" xlink:type="simple">10.1111/j.1468-1331.2009.02646.x</ext-link></comment> <object-id pub-id-type="pmid">19469830</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Corvol J-</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bonnet</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Charbonnier-Beaupel</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bonnet A-</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fi√©vet M-</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bellanger</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>The COMT Val158Met polymorphism affects the response to entacapone in Parkinson‚Äôs disease: a randomized crossover clinical trial</article-title>. <source>Ann Neurol</source>. <year>2011</year>;<volume>69</volume>: <fpage>111</fpage>‚Äì<lpage>118</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ana.22155" xlink:type="simple">10.1002/ana.22155</ext-link></comment> <object-id pub-id-type="pmid">21280081</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kremer</surname> <given-names>HPH</given-names></name>, <collab>Hungtington Study Group X</collab>. <article-title>Unified Huntington‚Äôs disease rating scale: reliability and consistency</article-title>. <source>Movement Disorders</source>. <year>1996</year>;<volume>11</volume>: <fpage>136</fpage>‚Äì<lpage>142</lpage>.</mixed-citation></ref>
<ref id="pone.0161106.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cardebat</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Doyon</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Puel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Goulet</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Joanette</surname> <given-names>Y</given-names></name>. <article-title>Evocation lexicale formelle et s√©mantique chez des sujets normaux. Performances et dynamiques de production en fonction du sexe, de l‚Äô√¢ge et du niveau d'√©tude</article-title>. <source>Acta Neurol Belg</source>. Acta medica belgica; <volume>90</volume>: <fpage>207</fpage>‚Äì<lpage>217</lpage>.</mixed-citation></ref>
<ref id="pone.0161106.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tabrizi</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Langbehn</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Leavitt</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Roos</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Durr</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Craufurd</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data</article-title>. <source>The Lancet Neurology</source>. <year>2009</year>; <volume>8</volume>(<issue>9</issue>): <fpage>791</fpage>‚Äì<lpage>801</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(09)70170-X" xlink:type="simple">10.1016/S1474-4422(09)70170-X</ext-link></comment> <object-id pub-id-type="pmid">19646924</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Langbehn</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Hayden</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Paulsen</surname> <given-names>JS</given-names></name>. <article-title>CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source>. <year>2010</year>;<volume>153B</volume>: <fpage>397</fpage>‚Äì<lpage>408</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.b.30992" xlink:type="simple">10.1002/ajmg.b.30992</ext-link></comment> <object-id pub-id-type="pmid">19548255</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shrout</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Fleiss</surname> <given-names>JL</given-names></name>. <article-title>Intraclass correlations: uses in assessing rater reliability</article-title>. <source>Psychol Bull</source>. <year>1979</year>;<volume>86</volume>: <fpage>420</fpage>‚Äì<lpage>428</lpage>. <object-id pub-id-type="pmid">18839484</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Proust‚ÄêLima</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Amieva</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Jacqmin‚ÄêGadda</surname> <given-names>H</given-names></name>. <article-title>Analysis of multivariate mixed longitudinal data: a flexible latent process approach</article-title>. <source>British Journal of Mathematical and Statistical Psychology</source>. <year>2013</year>;<volume>66</volume>(<issue>3</issue>): <fpage>470</fpage>‚Äì<lpage>487</lpage> <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bmsp.12000" xlink:type="simple">10.1111/bmsp.12000</ext-link></comment> <object-id pub-id-type="pmid">23082854</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Laird</surname> <given-names>NM</given-names></name>, <name name-style="western"><surname>Ware</surname> <given-names>JH</given-names></name>. <article-title>Random-effects models for longitudinal data</article-title>. <source>Biometrics</source>. <year>1982</year>;<volume>4</volume>: <fpage>963</fpage>‚Äì<lpage>974</lpage>.</mixed-citation></ref>
<ref id="pone.0161106.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zielonka</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Marinus</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Roos</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>De Michele</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Di Donato</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Putter</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>The influence of gender on phenotype and disease progression in patients with Huntington's disease</article-title>. <source>Parkinsonism and related disorders</source>. <year>2013</year>;<volume>19</volume>(<issue>2</issue>): <fpage>192</fpage>‚Äì<lpage>197</lpage> <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.parkreldis.2012.09.012" xlink:type="simple">10.1016/j.parkreldis.2012.09.012</ext-link></comment> <object-id pub-id-type="pmid">23102616</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bozdogan</surname> <given-names>H</given-names></name>. <article-title>Model selection and Akaike‚Äôs Information Criterion (AIC): The general theory and its analytical extensions</article-title>. <source>Psychometrika</source>. <year>1987</year>;<volume>52</volume>: <fpage>345</fpage>‚Äì<lpage>370</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF02294361" xlink:type="simple">10.1007/BF02294361</ext-link></comment></mixed-citation></ref>
<ref id="pone.0161106.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Palmatier</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Kidd</surname> <given-names>KK</given-names></name>. <article-title>Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles</article-title>. <source>Biol Psychiatry</source>. <year>1999</year>;<volume>46</volume>: <fpage>557</fpage>‚Äì<lpage>567</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0006-3223(99)00098-0" xlink:type="simple">10.1016/S0006-3223(99)00098-0</ext-link></comment> <object-id pub-id-type="pmid">10459407</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilson</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Hebert</surname> <given-names>LE</given-names></name>, <name name-style="western"><surname>Scherr</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Barnes</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>De Leon</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>DA</given-names></name>. <article-title>Educational attainment and cognitive decline in old age</article-title>. <source>Neurology</source>. <year>2009</year>;<volume>72</volume>(<issue>5</issue>): <fpage>460</fpage>‚Äì<lpage>465</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/01.wnl.0000341782.71418.6c" xlink:type="simple">10.1212/01.wnl.0000341782.71418.6c</ext-link></comment> <object-id pub-id-type="pmid">19188578</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kieburtz</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>MacDonald</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shih</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Feigin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Steinberg</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Bordwell</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Trinucleotide repeat length and progression of illness in Huntington's disease</article-title>. <source>Journal of medical genetics</source>. <year>1994</year>;<volume>31</volume>(<issue>11</issue>): <fpage>872</fpage>‚Äì<lpage>874</lpage>. <object-id pub-id-type="pmid">7853373</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brandt</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bylsma</surname> <given-names>FW</given-names></name>, <name name-style="western"><surname>Gross</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Stine</surname> <given-names>OC</given-names></name>, <name name-style="western"><surname>Ranen</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>CA</given-names></name>. <article-title>Trinucleotide repeat length and clinical progression in Huntington's disease</article-title>. <source>Neurology</source>. <year>1996</year>;<volume>46</volume>(<issue>2</issue>): <fpage>527</fpage>‚Äì<lpage>531</lpage>. <object-id pub-id-type="pmid">8614526</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tabrizi</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Scahill</surname> <given-names>RI</given-names></name>, <name name-style="western"><surname>Owen</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Durr</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Leavitt</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Roos</surname> <given-names>RA</given-names></name>, <etal>et al</etal>. <article-title>Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington‚Äôs disease in the TRACK-HD study: analysis of 36-month observational data</article-title>. <source>Lancet Neurol</source>. <year>2013</year>;<volume>12</volume>: <fpage>637</fpage>‚Äì<lpage>649</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(13)70088-7" xlink:type="simple">10.1016/S1474-4422(13)70088-7</ext-link></comment> <object-id pub-id-type="pmid">23664844</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>N√¶s</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mevik</surname> <given-names>B-H</given-names></name>. <article-title>Understanding the collinearity problem in regression and discriminant analysis</article-title>. <source>J Chemom</source>. <year>2001</year>;<volume>15</volume>(<issue>4</issue>): <fpage>413</fpage>‚Äì<lpage>26</lpage>.</mixed-citation></ref>
<ref id="pone.0161106.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vivot</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Glymour</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Tzourio</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Amouyel</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ch√™ne</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Dufouil</surname> <given-names>C</given-names></name>. <article-title>Association of Alzheimer‚Äôs related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study</article-title>. <source>Molecular psychiatry</source>. <year>2015</year>;<volume>20</volume>(<issue>10</issue>): <fpage>1173</fpage>‚Äì<lpage>1178</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/mp.2015.62" xlink:type="simple">10.1038/mp.2015.62</ext-link></comment> <object-id pub-id-type="pmid">26033242</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mura</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Proust-Lima</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Jacqmin-Gadda</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Akbaraly</surname> <given-names>TN</given-names></name>, <name name-style="western"><surname>Touchon</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dubois</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Measuring cognitive change in subjects with prodromal Alzheimer's disease</article-title>. <source>Journal of Neurology, Neurosurgery &amp; Psychiatry</source>. <year>2014</year>;<volume>85</volume>(<issue>4</issue>): <fpage>363</fpage>‚Äì<lpage>70</lpage>.</mixed-citation></ref>
<ref id="pone.0161106.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Biglan</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Shoulson</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kieburtz</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Oakes</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Kayson</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Shinaman</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials</article-title>. <source>JAMA neurology</source>. <year>2016</year>;<volume>73</volume>(<issue>1</issue>): <fpage>102</fpage>‚Äì<lpage>110</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jamaneurol.2015.2736" xlink:type="simple">10.1001/jamaneurol.2015.2736</ext-link></comment> <object-id pub-id-type="pmid">26569098</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Epping</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JI</given-names></name>, <name name-style="western"><surname>Craufurd</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Brashers-Krug</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Anderson</surname> <given-names>KE</given-names></name>, <name name-style="western"><surname>McCusker</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Longitudinal Psychiatric Symptoms in Prodromal Huntington‚Äôs Disease: A Decade of Data</article-title>. <source>American Journal of Psychiatry</source>. <year>2016</year>;<volume>173</volume>(<issue>2</issue>): <fpage>184</fpage>‚Äì<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1176/appi.ajp.2015.14121551" xlink:type="simple">10.1176/appi.ajp.2015.14121551</ext-link></comment> <object-id pub-id-type="pmid">26472629</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vuono</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Winder-Rhodes</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>De Silva</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Cisbani</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Drouin-Ouellet</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Spillantini</surname> <given-names>MG</given-names></name> <etal>et al</etal>. <article-title>The role of tau in the pathological process and clinical expression of Huntington‚Äôs disease</article-title>. <source>Brain</source>. <year>2015</year>;<volume>138</volume>(<issue>7</issue>): <fpage>1907</fpage>‚Äì<lpage>1918</lpage>.</mixed-citation></ref>
<ref id="pone.0161106.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Williams-Gray</surname> <given-names>CH</given-names></name>, <name name-style="western"><surname>Hampshire</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Barker</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Owen</surname> <given-names>AM</given-names></name>. <article-title>Attentional control in Parkinson‚Äôs disease is dependent on COMT val158met genotype</article-title>. <source>Brain</source>. <year>2008</year>;<volume>131</volume>: <fpage>397</fpage>‚Äì<lpage>408</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/brain/awm313" xlink:type="simple">10.1093/brain/awm313</ext-link></comment> <object-id pub-id-type="pmid">18178571</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gennatas</surname> <given-names>ED</given-names></name>, <name name-style="western"><surname>Cholfin</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Crawford</surname> <given-names>RK</given-names></name>, <name name-style="western"><surname>Sasaki</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Karydas</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>COMT Val158Met genotype influences neurodegeneration within dopamine-innervated brain structures</article-title>. <source>Neurology</source>. <year>2012</year>;<volume>78</volume>: <fpage>1663</fpage>‚Äì<lpage>1669</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0b013e3182574fa1" xlink:type="simple">10.1212/WNL.0b013e3182574fa1</ext-link></comment> <object-id pub-id-type="pmid">22573634</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Cepeda</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Levine</surname> <given-names>MS</given-names></name>. <article-title>Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility</article-title>. <source>Front Neurosci</source>. <year>2013</year>;<volume>7</volume>: <fpage>114</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fnins.2013.00114" xlink:type="simple">10.3389/fnins.2013.00114</ext-link></comment> <object-id pub-id-type="pmid">23847463</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cools</surname> <given-names>R</given-names></name>. <article-title>Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2006</year>;<volume>30</volume>(<issue>1</issue>): <fpage>1</fpage>‚Äì<lpage>23</lpage>. <object-id pub-id-type="pmid">15935475</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Frank</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Fossella</surname> <given-names>JA</given-names></name>. <article-title>Neurogenetics and pharmacology of learning, motivation, and cognition</article-title>. <source>Neuropsychopharmacology</source>. Nature Publishing Group. <year>2011</year>;<volume>36</volume>: <fpage>133</fpage>‚Äì<lpage>152</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/npp.2010.96" xlink:type="simple">10.1038/npp.2010.96</ext-link></comment> <object-id pub-id-type="pmid">20631684</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Charvin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Roze</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Perrin</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Deyts</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Betuing</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pag√®s</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo</article-title>. <source>Neurobiol Dis</source>. <year>2008</year>;<volume>29</volume>: <fpage>22</fpage>‚Äì<lpage>29</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2007.07.028" xlink:type="simple">10.1016/j.nbd.2007.07.028</ext-link></comment> <object-id pub-id-type="pmid">17905594</object-id></mixed-citation></ref>
<ref id="pone.0161106.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwab</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Garas</surname> <given-names>SN</given-names></name>, <name name-style="western"><surname>Drouin-Ouellet</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mason</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Stott</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Barker</surname> <given-names>RA</given-names></name>. <article-title>Dopamine and Huntington‚Äôs disease</article-title>. <source>Expert Rev Neurother</source>. <year>2015</year>;<volume>15</volume>: <fpage>445</fpage>‚Äì<lpage>458</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1586/14737175.2015.1025383" xlink:type="simple">10.1586/14737175.2015.1025383</ext-link></comment> <object-id pub-id-type="pmid">25773746</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>